Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.260
+0.110 (3.49%)
At close: Aug 11, 2026, 4:00 PM EDT
3.251
-0.009 (-0.29%)
After-hours: Aug 11, 2026, 7:52 PM EDT

Prime Medicine Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Prime Medicine stock has a consensus rating of "Buy" and an average price target of $7.03. The average 1-year stock price forecast is 115.64% higher than the current stock price, while the lowest is $4.25 (+30.37%) and the highest is $11 (+237.42%).

Price Target: $7.03 (+115.64%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$4.25$7.03$7.00$11
Change+30.37%+115.64%+114.72%+237.42%

Analyst Ratings

The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy888998
Buy111111
Hold444333
Sell000000
Strong Sell000000
Total131313131312

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Hold
Reiterates
n/a
HoldReiteratesn/an/aAug 10, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$8
BuyMaintains$8+145.40%Aug 10, 2026
JonesTrading
JonesTrading
Buy
Maintains
$5
BuyMaintains$5+53.37%Aug 6, 2026
LifeSci Capital
LifeSci Capital
Buy
Maintains
$6
BuyMaintains$6+84.05%Aug 6, 2026
Oppenheimer
Oppenheimer
Buy
Reiterates
$11
BuyReiterates$11+237.42%Jul 24, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
10.79M
from 4.63M
Increased by 132.94%
Revenue Next Year
11.58M
from 10.79M
Increased by 7.31%
EPS This Year
-0.93
from -1.35
EPS Next Year
-0.89
from -0.93
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
---2.98M4.63M10.79M
Revenue Growth
----55.28%132.94%
Operating Income
-84.47M-116.54M-191.29M-202.47M-208.35M-176.74M
Net Income
-165.37M-121.82M-198.13M-195.88M-201.14M-176.04M
EPS
-----1.35-0.93
Free Cash Flow
-6.80M-117.62M-96.21M-114.57M-85.37M-175.21M
No. Analysts
-----10
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High53.0M
Avg10.8M
Low2.0M

Revenue Growth

Revenue Growth202620272028
High
1,044.4%
Avg
132.9%
Low
-56.8%

EPS Forecast

EPS202620272028
High-0.82
Avg-0.93
Low-1.02

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-